- 4 Stocks Under $10 to Trade for Breakouts
- 3 Stocks Under $10 Making Big Moves
- 5 Stocks Under $10 Moving Higher
- 5 Stocks Under $10 Set to Soar
- 5 Big Trades to Take in December
17 Breakout Stocks to Watch This Week - 21783 views
The following commentary comes from an independent investor or market observer as part of TheStreet’s guest contributor program, which is separate from the company’s news coverage. The opinions expressed are those of the author and do not represent the views of TheStreet or its management.
NEW YORK (Scott's Investments) -- Each week I publish stocks to watch for the upcoming week as potential momentum trades or longer-term investments. The stocks below all have a 50,000 minimum average daily share volume and traded at a 52-week high on strong volume, with a minimum of two times relative volume on Friday, June 17. In addition, stocks were required to close Friday higher than the open price. The full list with weekly performance is tracked on the right-hand side of Scott's Investments.
More From Stockpickr
Last week only nine stocks made the cut, while this week the list has expanded to 17 stocks. I have used this list more as a way to generate longer-term investment ideas, especially since very short-term momentum trading is not objective and since stocks that have risen dramatically can have a tendency to consolidate in the short-term. For example, PriceSmart (PSMT) was featured in my May 6 list and had volatile price action in subsequent weeks. After waiting for PSMT to form a wedge pattern last week, I initiated a long position, betting on a breakout. I like the long-term growth prospects of PSMT and technicals; however, my long position was not initiated until over a month after it appeared on my "Stocks to Watch This Week" list.
With that being said, one highly speculative biotechnology stock caught my eye on this week's list. Oncothyreon (ONTY) is an intriguing long-term biotechnology company with a parabolic chart:
The recent rise in share price is due in part to increased attention on cancer vaccines as revolutionary treatments for cancer. ONTY announced on May 24 that it "initiated the Phase 2 portion of its ongoing Phase 1/2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab (Erbitux®) following successful completion of the Phase 1 dose escalation portion of the study." According to the company, "PX-866 has been shown to induce prolonged inhibition of tumor PI-3-kinase signaling, and has demonstrated anti-tumor activity both as a single agent and in combination with other agents in a number of human tumor models." While approval of the drug could be several years away, any future updates on the trial could serve as a further catalyst.
The company raised $43 million in early May via an equity offering at $4 a share, which, while dilutive, provides the company with additional capital to complete current trials. The company also has Stimuvax, currently in a Phase 3 pivotal trial. According to the company, Stimuvax is "an innovative cancer vaccine designed to induce an immune response to cancer cells that express MUC1, a protein antigen widely expressed on common cancers. MUC1 is over expressed on many cancers such as lung cancer, breast cancer, prostate cancer and colorectal cancer. Stimuvax is thought to work by stimulating the body's immune system to identify and destroy cancer cells expressing MUC1."
Should Stimuvax phase 3 trials lead to an FDA approval, the company's market value could see a dramatic increase. With a current capitalization of $336 million, the market is just beginning to price in the "potential" for clinical success. Clinical-stage bio-pharmaceutical companies are gambles: without any clinical success, the company can quickly become near-worthless. However, given that ONTY has 2 clinical stage drugs targeting diseases that afflict millions each year, it will be a stock worth watching in the coming weeks and months. Clinical stage companies can see dramatic moves based on news, so it is a highly speculative investment at this point. Given the recent meteoric rise, a short-term pullback could also be looming.
Below are the rest of this week's stocks to watch:
Scott's Investments focuses on consolidating and tracking free online investment resources for the public with an emphasis on ETFs, portfolio/trading strategies and macroeconomics. Follow Scott's Investments on Twitter.